Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

Analysis Finds Higher Outpatient Drug Spending At 340B Hospitals

March 14, 2018

A new analysis finds hospitals participating in the 340B Drug Discount Program have higher per patient outpatient pharmacy costs than their non-340B counterparts – meaning patients at 340B hospitals are prescribed more medicines and/or more expensive medicines.

Read More

Value-Based Contracts May Lower Patients’ Out-of-Pocket Costs by 28 Percent

February 26, 2018

In the past two years, commercially insured patients in health plans with value-based contracts for diabetes, high cholesterol and HIV medicines had copays that were, on average, 28 percent lower for those medicines compared to patients in other plans

Read More

PhRMA Statement on President’s FY2019 Budget

February 12, 2018

PhRMA president & CEO Stephen J. Ubl issued a statement on President Donald Trump’s FY2019 budget request.

Read More

PhRMA Statement on Part D Provision in Budget Deal

February 8, 2018

Today, PhRMA President and CEO Stephen J. Ubl provided the following statement:

Read More

Amgen CEO Robert A. Bradway Becomes PhRMA Board Chairman

February 7, 2018

The Pharmaceutical Research and Manufacturers of America (PhRMA) held its board meeting today, officially welcoming three new elected officers. Robert A. Bradway, chairman and CEO, Amgen, became chairman of the PhRMA board of directors

Read More

PhRMA Statement on HELP ACT

January 17, 2018

Today, Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl provided the following statement.

Read More

PhRMA Statement on Comments to CMS Regarding Proposed Part D Rule and RFI Exploring Pass-Through Rebates to Seniors at Point of Sale

January 16, 2018

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments to the Centers for Medicare & Medicaid Services regarding the proposed rule, “Contract Year 2019 Policy and Technical Changes to the Medicare Advantage Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program.”

Read More

PhRMA Statement on 340B PAUSE Act

December 21, 2017

The legislation introduced today by Representatives Larry Bucshon and Scott Peters is yet another important action taken this year to begin to address the problems in the 340B program.

Read More

PhRMA Announces Major Commitment to Address the Opioid Crisis in America

December 12, 2017

PhRMA announced a new multi-year, multimillion dollar initiative to address the opioid crisis, which will include a partnership with the Addiction Policy Forum to fund state and local programs, as well as support for new public policies that help families and individuals impacted by the crisis.

Read More
prev 1 2 3 4 5 6 next